Author + information
- Received July 16, 2018
- Revision received November 14, 2018
- Accepted January 4, 2019
- Published online March 13, 2019.
- Ryan S. Dolan, MDa,∗ (, )
- Amir A. Rahsepar, MDa,
- Julie Blaisdell, MSa,
- Kenichiro Suwa, MDa,
- Kambiz Ghafourian, MD, MPHb,
- Jane E. Wilcox, MD, MScb,
- Sadiya S. Khan, MD, MScb,
- Esther E. Vorovich, MDb,
- Jonathan D. Rich, MDb,
- Allen S. Anderson, MDb,
- Clyde W. Yancy, MDb,
- Jeremy D. Collins, MDa,
- James C. Carr, MDa and
- Michael Markl, PhDa,c
- aDepartment of Radiology, Northwestern University, Chicago, Illinois
- bDepartment of Cardiology, Northwestern University, Chicago, Illinois
- cDepartment of Biomedical Engineering, Northwestern University, Chicago, Illinois
- ↵∗Address for correspondence:
Dr. Ryan Dolan, Northwestern University School of Medicine, Department of Radiology, 737 N. Michigan Avenue, Suite 1600, Chicago, Illinois 60611.
Objectives The purpose of this study was to evaluate the sensitivity of multiparametric cardiac magnetic resonance imaging (CMR) for the detection of acute cardiac allograft rejection (ACAR).
Background ACAR is currently diagnosed by endomyocardial biopsy, but CMR may be a noninvasive alternative because of its capacity for regional myocardial structure and function characterization.
Methods Fifty-eight transplant recipients (mean age 47.0 ± 14.7 years) and 14 control subjects (mean age 47.7 ± 16.7 years) were prospectively recruited from August 2014 to May 2017 and underwent 97 CMR studies (83 transplant recipients, 14 control subjects) for assessment of global left ventricular function and myocardial T2, T1, and extracellular volume fraction (ECV). CMR studies were divided into 4 groups on the basis of biopsy grade: control subjects (n = 14), patients with no ACAR (no history of ACAR; n = 36), patients with past ACAR (history of ACAR; n = 24), and ACAR+ patients (active grade ≥1R ACAR; n = 23).
Results Myocardial T2 was significantly higher in patients with past ACAR compared with those with no ACAR (51.0 ± 3.8 ms vs. 49.2 ± 4.0 ms; p = 0.02) and in patients with no ACAR compared with control subjects (49.2 ± 4.0 ms vs. 45.2 ± 2.3 ms; p < 0.01). ACAR+ patients demonstrated increased T2 compared with the no ACAR group (52.4 ± 4.7 ms vs. 49.2 ± 4.0 ms, p < 0.01) but not compared with the past ACAR group. In contrast, ECV was significantly elevated in ACAR+ patients compared with transplant recipients without ACAR regardless of history of ACAR (no ACAR: 31.5 ± 3.9% vs. 26.8 ± 3.3% [p < 0.01]; past ACAR: 31.5 ± 3.9% vs. 26.8 ± 4.0% [p < 0.01]). Receiver operating characteristic curve analysis revealed that a combined model of age at CMR, global T2, and global ECV was predictive of ACAR (area under the curve = 0.84).
Conclusions The combination of CMR-derived myocardial T2 and ECV has potential as a noninvasive tissue biomarker for ACAR. Larger studies during acute ACAR are needed for continued development of multiparametric CMR for transplant recipient surveillance.
This work was funded by grant R01 HL117888 from the National Heart, Lung, and Blood Institute. The authors have reported that they have no relationships relevant to the contents of this paper to disclose.
- Received July 16, 2018.
- Revision received November 14, 2018.
- Accepted January 4, 2019.
- 2019 American College of Cardiology Foundation
This article requires a subscription or purchase to view the full text. If you are a subscriber or member, click Login or the Subscribe link (top menu above) to access this article.